Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trineumin in Neurofibromatosis Type II
NCT07131722Phase 2Not yet recruiting
- Sponsor
- PRG Science & Technology
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Trineumin in neurofibromatosis type 2 (NF2), sponsored by PRG Science & Technology. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Trineumin
03
Conditions
neurofibromatosis type 2 (NF2)
Beyond the preview
Go deeper on NCT07131722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131722.